RxDoctor Payments Data

Syed Azam, MD

Internal Medicine · Rancho Mirage, CANPI 1811993454

Payments from drug & device makers

$4,613in general payments, 2019–2025

Across 249 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$425
  • Lilly USA, LLC$347
  • Pfizer$328
  • GSK$299
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$221
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,58599%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,613 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$812,840
Medicare patients
712
Services billed
12,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$241,451
MounjaroTirzepatide205$217,718
JardianceEmpagliflozin171$197,190
TrulicityDulaglutide67$99,689
EliquisApixaban36$41,838
WegovySemaglutide28$41,413
XareltoRivaroxaban32$39,716
FarxigaDapagliflozin Propanediol32$36,706
EntrestoSacubitril/Valsartan27$29,338
SteglatroErtugliflozin Pidolate34$27,133
Arnuity ElliptaFluticasone Furoate70$26,795
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$24,605
Spiriva RespimatTiotropium Bromide29$24,375
Incruse ElliptaUmeclidinium Bromide45$23,435
LinzessLinaclotide21$21,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$347$317,407272 claims
Novo NordiskOzempic, Wegovy$1,001$282,864200 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$91$242,475219 claims
GSKArnuity Ellipta, Incruse Ellipta, Breo Ellipta, Shingrix$299$72,212166 claims
Johnson & JohnsonXarelto, Invokana$179$57,58445 claims
PfizerEliquis$328$41,83836 claims
AstraZenecaFarxiga$193$36,70632 claims
NovartisEntresto$68$29,33827 claims
MerckSteglatro$173$27,13334 claims
AbbVieLinzess, Synthroid$218$24,78352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →